Literature DB >> 31537690

Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts (<10%) or with other types of disease progression.

Julia T Geyer1, Elizabeth Margolskee2, Spencer A Krichevsky3, Daniele Cattaneo4, Leonardo Boiocchi5, Paola Ronchi6, Francesca Lunghi6, Joseph M Scandura3, Maurilio Ponzoni6, Robert P Hasserjian5, Umberto Gianelli7, Alessandra Iurlo4, Attilio Orazi8.   

Abstract

Entities:  

Year:  2019        PMID： 31537690      PMCID： PMC7193506          DOI： 10.3324/haematol.2019.230193

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Monocytosis in polycythemia vera: Clinical and molecular correlates.

Authors:  Daniela Barraco; Sonia Cerquozzi; Naseema Gangat; Mrinal M Patnaik; Terra Lasho; Christy Finke; Curtis A Hanson; Rhett P Ketterling; Animesh Pardanani; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2017-05-26       Impact factor: 10.047

2.  MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.

Authors:  Paola Guglielmelli; Terra L Lasho; Giada Rotunno; Mythri Mudireddy; Carmela Mannarelli; Maura Nicolosi; Annalisa Pacilli; Animesh Pardanani; Elisa Rumi; Vittorio Rosti; Curtis A Hanson; Francesco Mannelli; Rhett P Ketterling; Naseema Gangat; Alessandro Rambaldi; Francesco Passamonti; Giovanni Barosi; Tiziano Barbui; Mario Cazzola; Alessandro M Vannucchi; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2017-12-09       Impact factor: 44.544

3.  Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease.

Authors:  Leonardo Boiocchi; Rosanny Espinal-Witter; Julia Turbiner Geyer; Julia Steinhilber; Irina Bonzheim; Daniel M Knowles; Falko Fend; Attilio Orazi
Journal:  Mod Pathol       Date:  2012-09-28       Impact factor: 7.842

4.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

Authors:  Francisco Cervantes; Brigitte Dupriez; Arturo Pereira; Francesco Passamonti; John T Reilly; Enrica Morra; Alessandro M Vannucchi; Ruben A Mesa; Jean-Loup Demory; Giovanni Barosi; Elisa Rumi; Ayalew Tefferi
Journal:  Blood       Date:  2008-11-06       Impact factor: 22.113

5.  Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications.

Authors:  Leonardo Boiocchi; Umberto Gianelli; Alessandra Iurlo; Falko Fend; Irina Bonzheim; Daniele Cattaneo; Daniel M Knowles; Attilio Orazi
Journal:  Mod Pathol       Date:  2015-09-04       Impact factor: 7.842

Review 6.  Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options.

Authors:  Alessandra Iurlo; Daniele Cattaneo; Umberto Gianelli
Journal:  Int J Mol Sci       Date:  2019-04-13       Impact factor: 5.923

7.  Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.

Authors:  A Tefferi; E Rumi; G Finazzi; H Gisslinger; A M Vannucchi; F Rodeghiero; M L Randi; R Vaidya; M Cazzola; A Rambaldi; B Gisslinger; L Pieri; M Ruggeri; I Bertozzi; N H Sulai; I Casetti; A Carobbio; G Jeryczynski; D R Larson; L Müllauer; A Pardanani; J Thiele; F Passamonti; T Barbui
Journal:  Leukemia       Date:  2013-06-06       Impact factor: 11.528

8.  Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts.

Authors:  Ayalew Tefferi; Mythri Mudireddy; Francesco Mannelli; Kebede H Begna; Mrinal M Patnaik; Curtis A Hanson; Rhett P Ketterling; Naseema Gangat; Meera Yogarajah; Valerio De Stefano; Francesco Passamonti; Vittorio Rosti; Maria Chiara Finazzi; Alessandro Rambaldi; Alberto Bosi; Paola Guglielmelli; Animesh Pardanani; Alessandro M Vannucchi
Journal:  Leukemia       Date:  2018-02-02       Impact factor: 11.528

9.  Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis.

Authors:  Mythri Mudireddy; Naseema Gangat; Curtis A Hanson; Rhett P Ketterling; Animesh Pardanani; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2018-06-11       Impact factor: 11.037

10.  Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model.

Authors:  Rangit R Vallapureddy; Mythri Mudireddy; Domenico Penna; Terra L Lasho; Christy M Finke; Curtis A Hanson; Rhett P Ketterling; Kebede H Begna; Naseema Gangat; Animesh Pardanani; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2019-01-25       Impact factor: 11.037
View more
  3 in total

1.  Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era.

Authors:  Lucia Masarova; Prithviraj Bose; Naveen Pemmaraju; Naval G Daver; Lingsha Zhou; Sherry Pierce; Koji Sasaki; Hagop M Kantarjian; Zeev Estrov; Srdan Verstovsek
Journal:  Cancer       Date:  2020-07-22       Impact factor: 6.860

Review 2.  Accelerated Phase of Myeloproliferative Neoplasms.

Authors:  Omar A Shahin; Helen T Chifotides; Prithviraj Bose; Lucia Masarova; Srdan Verstovsek
Journal:  Acta Haematol       Date:  2021-04-21       Impact factor: 2.195

3.  Triple-Negative Essential Thrombocythemia: Clinical-Pathological and Molecular Features. A Single-Center Cohort Study.

Authors:  Daniele Cattaneo; Giorgio Alberto Croci; Cristina Bucelli; Silvia Tabano; Marta Giulia Cannone; Gabriella Gaudioso; Maria Chiara Barbanti; Kordelia Barbullushi; Paola Bianchi; Elisa Fermo; Sonia Fabris; Luca Baldini; Umberto Gianelli; Alessandra Iurlo
Journal:  Front Oncol       Date:  2021-03-12       Impact factor: 6.244
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.